JonesTrading analyst Soumit Roy has maintained their neutral stance on BOLT stock, giving a Hold rating on July 30.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Hold rating due to a combination of factors surrounding Bolt Biotherapeutics. The ongoing Phase 1/2 trial for the BDC-4182 program, which targets Claudin 18.2 in solid tumors, is still in its early stages, with preliminary efficacy data expected in the first half of 2026. The trial’s outcome is uncertain, as it involves patients with varying levels of CLDN18.2 expression, potentially leading to mixed results.
Additionally, while the BDC-4182 has shown promising preclinical results and an acceptable safety profile in non-human primates, its competitive standing against other CLDN18.2 targeting therapies remains to be seen. Financially, the company holds approximately $48.5 million in cash, which is projected to sustain operations until mid-2026. These factors contribute to a cautious outlook, warranting a Hold rating until more definitive clinical data is available.
According to TipRanks, Roy is an analyst with an average return of -22.3% and a 20.56% success rate. Roy covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Nuvation Bio, and Precision BioSciences.
In another report released on July 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.00 price target.